Merck Fosamax
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
A two-year study of 10 mg alendronate daily in 241 men with osteoporosis shows mean bone mineral density increases of 7.1±0.3% at the lumbar spine, 2.5±0.4% at the femoral neck, and 2.0±0.2% for the total body. Placebo patients saw a 1.8±0.5% increase in BMD at the lumbar spine and no significant changes in femoral neck or total body BMD, investigators reported in the New England Journal of Medicine Aug. 31. The results were similar to one-year data announced last fall. Merck has an sNDA with priority review status pending at FDA for treatment of male osteoporosi
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.